Literature DB >> 17823079

Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells.

Madeleine Collette1, Géraldine Descamps, Catherine Pellat-Deceunynck, Régis Bataille, Martine Amiot.   

Abstract

In multiple myeloma, a large number of growth factors (IL-6, IGF-1, FGF, HGF and HB-EGF) are involved in promoting myeloma cell growth. In the present study, a serum-free, cytokine-free, collagen-based assay, which does not allow the generation of spontaneous myeloma colonies, was used to identify the clonogenic growth factors for fourteen myeloma cell lines. IL-6 is the only clonogenic factor able to stimulate both CD45+ and CD45- myeloma cell lines, generating myeloma colonies from 10 out of 14 myeloma cell lines. Using a pharmacological Erk inhibitor, we show that the Erk/MAPK pathway is involved in IL-6-induced clonogenicity of CD45+, but not CD45- myeloma cell lines. In contrast to IL-6, the other growth factors (IGF-1, FGF, HGF and HB-EGF) stimulate only some myeloma cell lines, but always CD45-, and less effectively than IL-6. Among them, IGF-1 is the most potent, generating myeloma colonies from five out of eight CD45- myeloma cell lines. Finally, the capacity of IGF-1 and FGF to stimulate the clonogenicity of CD45- myeloma cells correlates with their ability to stimulate the Erk/MAPK pathway. We conclude that CD45 expression plays a crucial role in determining signaling and proliferation of human myeloma cell responses to IL-6, IGF-1 and other growth factors. The poor outcome of CD45- myeloma patients could be related to the capacity of CD45-myeloma cells to take advantage of multiple growth factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823079     DOI: 10.1684/ecn.2007.0095

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  7 in total

1.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

2.  Bone marrow-derived cells are not the origin of the cancer stem cells in ultraviolet-induced skin cancer.

Authors:  Satomi Ando; Riichiro Abe; Mikako Sasaki; Junko Murata; Daisuke Inokuma; Hiroshi Shimizu
Journal:  Am J Pathol       Date:  2009-01-08       Impact factor: 4.307

3.  Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Authors:  D Chiron; S Maïga; S Surget; G Descamps; P Gomez-Bougie; S Traore; N Robillard; P Moreau; S Le Gouill; R Bataille; M Amiot; C Pellat-Deceunynck
Journal:  Blood Cancer J       Date:  2013-06-07       Impact factor: 11.037

4.  Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.

Authors:  Shuoling Chen; Chang Gao; Yangyuan Wu; Zunnan Huang
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

5.  Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.

Authors:  S Maïga; P Gomez-Bougie; S Bonnaud; C Gratas; P Moreau; S Le Gouill; C Pellat-Deceunynck; M Amiot
Journal:  Br J Cancer       Date:  2013-04-30       Impact factor: 7.640

6.  Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event.

Authors:  Jean-Pascal Capp; Régis Bataille
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244

7.  Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma.

Authors:  Zhenfeng Deng; Jilong Wang; Banghao Xu; Zongrui Jin; Guolin Wu; Jingjing Zeng; Minhao Peng; Ya Guo; Zhang Wen
Journal:  Biomed Res Int       Date:  2019-11-19       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.